On HIV diversity

AIDS

Volumn 26, Issue 10, 2012, Pages 1255-1260

  Ndung'U, Thumbi ^a,b   Weiss, Robin A ^c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antigenic diversity; evolution; genetic diversity; HIV

Indexed keywords

ANTIVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; CLINICAL TRIAL; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TROPISM; VIRULENCE; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

HIV INFECTIONS; HIV-1; HUMANS; MUTATION RATE; VIRUS REPLICATION;

EID: 84862737670     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835461b5     Document Type: Review

References (63)

1. Levy JA. HIV and the pathogenesis of AIDS. 3rd ed. Washington: ASM Press; 2007.
2. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58:19-42. (Pubitemid 33070762)
3. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354:453-459. (Pubitemid 21896855)
4. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312. (Pubitemid 36378357)
5. Malim MH. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 2009; 364:675-687.
6. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362:359-362. (Pubitemid 23101311)
7. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362:355-358. (Pubitemid 23101310)
8. Bhattacharya B, Weiss RA, Davis C, Holmes H, Hockley D, Fassati A. Detection and quantitation of human immunodeficiency virus type-1 particles by confocal microscopy. J Virol Methods 2004; 120:13-21. (Pubitemid 38968652)
9. Layne SP, Merges MJ, Dembo M, Spouge JL, Conley SR, Moore JP, et al. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 1992; 189:695-714.
10. Luciw PA, Potter SJ, Steimer K, Dina D, Levy JA. Molecular cloning of AIDS-associated retrovirus. Nature 1984; 312:760-763. (Pubitemid 15195923)
11. Wain-Hobson S, Vartanian JP, Henry M, Chenciner N, Cheynier R, Delassus S, et al. LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. Science 1991; 252:961-965. (Pubitemid 21917014)
12. Trask SA, Derdeyn CA, Fideli U, Chen Y, Meleth S, Kasolo F, et al. Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. J Virol 2002; 76:397-405. (Pubitemid 33139024)
13. Paprotka T, Delviks-Frankenberry KA, Cingoz O, Martinez A, Kung HJ, Tepper CG, et al. Recombinant origin of the retrovirus XMRV. Science 2011; 333:97-101.
14. Baillie GJ, Galiano M, Agapow PM, Myers R, Chiam R, Gall A, et al. Evolutionary dynamics of local pandemic H1N1/2009 influenza virus lineages revealed by whole-genome analysis. J Virol 2012; 86:11-18.
15. Pepin J. The origins of AIDS. Cambridge, UK: Cambridge University Press; 2011.
16. Sharp PM, Hahn BH. The evolution of HIV-1 and the origin of AIDS. Philos Trans R Soc Lond B Biol Sci 2010; 365:2487-2494.
17. Bieniasz PD. An overview of intracellular interactions between immunodeficiency viruses and their hosts. AIDS 2012; 26:1243-1254.
18. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, et al. HIV-1 nomenclature proposal. Science 2000; 288:55-56.
19. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25:679-689.
20. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009; 458:641-645.
21. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296:1439-1443. (Pubitemid 34553083)
22. John-Stewart GC, Nduati RW, Rousseau CM, Mbori-Ngacha DA, Richardson BA, Rainwater S, et al. Subtype C Is associated with increased vaginal shedding of HIV-1. J Infect Dis 2005; 192:492-496. (Pubitemid 41023129)
23. Kaleebu P, Ross A, Morgan D, Yirrell D, Oram J, Rutebemberwa A, et al. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2001; 15:293-299. (Pubitemid 32163814)
24. Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, de Ruiter A, et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 2010; 13:4.
25. Dreja H, O'Sullivan E, Pade C, Greene KM, Gao H, Aubin K, et al. Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. J Gen Virol 2010; 91:2794-2803.
26. Herbeck JT, Muller V, Maust BS, Ledergerber B, Torti C, Di Giambenedetto S, et al. Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. AIDS 2012; 26:193-205.
27. Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, Brumme CJ, et al. Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J Virol 2010; 84:10820-10831.
28. Weiss RA. Virulence and pathogenesis. Trends Microbiol 2002; 10:314-317. (Pubitemid 34756530)
29. Forsman A, Weiss RA. Why is HIV a pathogen? Trends Microbiol 2008; 16:555-560.
30. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. CD4R T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759. (Pubitemid 39299461)
31. Veazey RS, Lackner AA. Getting to the guts of HIV pathogenesis. J Exp Med 2004; 200:697-700. (Pubitemid 39299456)
32. Mellors J, Kingsley L, Rinaldo CJ, Todd J, Hoo B, Kokka R, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Inter Med 1995; 122:573-579.
33. Roberts L, Passmore JA, Mlisana K, Williamson C, Little F, Bebell LM, et al. Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis 2012; 205:194-203.
34. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.
35. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011; 364:1943-1954.
36. Koup RA. Virus escape from CTL recognition. J Exp Med 1994; 180:779-782. (Pubitemid 24256591)
37. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 2005; 102:18514-18519. (Pubitemid 43011257)
38. Aasa-Chapman MM, Cheney KM, Hue S, Forsman A, O'Farrell S, Pellegrino P, et al. In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies. PLoS One 2011; 6:e23961.
39. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, et al. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 2009; 5:e1000414.
40. Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, Fischer U, et al. Recombination: multiply infected spleen cells in HIV patients. Nature 2002; 418:144. (Pubitemid 34773761)
41. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 2004; 199:283-293. (Pubitemid 38129707)
42. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, et al. A new classification for HIV-1. Nature 1998; 391:240.
43. Chun T-W, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012; 26:1261-1268.
44. Duenas-Decamp MJ, Peters PJ, Repik A, Musich T, Gonzalez-Perez MP, Caron C, et al. Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis. Future Virol 2010; 5:435-451.
45. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169:968-974. (Pubitemid 24303213)
46. Sucupira MC, Sanabani S, Cortes RM, Giret MT, Tomiyama H, Sauer MM, et al. Faster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strains. PLoS One 2012; 7:e30292.
47. Abebe A, Demissie D, Goudsmit J, Brouwer M, Kuiken CL, Pollakis G, et al. HIV-1 subtype C syncytium-and nonsyncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 1999; 13:1305-1311. (Pubitemid 29408444)
48. Ping L, Nelson J, Hoffman I, Schock J, Lamers S, Goodman M, et al. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol 1999; 73:6271-6281. (Pubitemid 29327803)
49. Vella S, Schwartländer B, Sow SP, Eholie SP, Murphy RL. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS 2012; 26:1231-1241.
50. Liow LH, Van Valen L, Stenseth NC. Red Queen: from populations to taxa and communities. Trends Ecol Evol 2011; 26:349-358.
51. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
52. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
53. Laga M, Piot P. Prevention of sexual transmission of HIV: real results, science progressing, societies remaining behind. AIDS 2012; 26:1223-1229.
54. Saunders KO, Rudicell RS, Nabel GJ. The design and evaluation of HIV-1 vaccines. AIDS 2012; 26:1293-1302.
55. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333:1633-1637.
56. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329:811-817.
57. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-470.
58. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-289.
59. Bonsignori M, Montefiori DC, Wu X, Chen X, Hwang KK, Tsao CY, et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol 2012; 88:4688-4692.
60. Liu P, Overman RG, Yates NL, Alam SM, Vandergrift N, Chen Y, et al. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J Virol 2011; 85:11196-11207.
61. Willey S, Aasa-Chapman MM. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol 2008; 16:596-604.
62. Burton DR, Weiss RA. AIDS/HIV. A boost for HIV vaccine design. Science 2010; 329:770-773.
63. McDermott AB, Koup RA. CD8R T cells in preventing HIV infection. AIDS 2012; 26:1281-1292.